(0)サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1702013

がん診断市場：製品別、技術別、適応別、エンドユーザー別、地域別、2025-2033年

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 145 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
がん診断市場：製品別、技術別、適応別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年04月01日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん診断市場の世界市場規模は2024年に2,079億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに3,262億米ドルに達し、2025年から2033年にかけて4.88%の成長率（CAGR）を示すと予測しています。疾病の早期発見に対する意識の高まり、ライフスタイルの変化や遺伝的素因によるがんの有病率の上昇、患者ケアを強化するための診断技術の進歩などが、市場を推進する主な要因です。

がん診断は、個人のがんの存在、タイプ、ステージを特定し判定します。これは、血液、組織、遺伝子サンプルを分析する磁気共鳴画像法（MRI）、X線、臨床検査など、さまざまな技術や手法で構成されています。これにより医療専門家は、体内のがん性増殖を正確に検出し評価することができます。また、医療プロバイダーは、疾患の特性に合わせた介入を行うことで、患者の転帰を最適化することができます。治療方針の決定や個別化された治療戦略の開発に役立ちます。

現在、個人の間で不快感や侵襲性を最小限に抑える非侵襲的診断アプローチへの嗜好が高まっていることが、市場の成長に寄与しています。これに加えて、費用対効果が高く正確な診断技術に対する需要の高まりが、市場の成長を強化しています。これに伴い、より迅速で正確な結果を可能にするために、がん診断における人工知能（AI）、機械学習（ML）、データ分析の統合が進んでいることが、市場の成長を促進しています。これとは別に、いくつかの国の行政機関や医療当局は、世界中の大衆にがんとその診断に関する認識を広めるためのキャンペーンを実施しています。さらに、個別化された医薬品に対する需要の高まりは、世界中の医療インフラの改善とともに、市場に明るい展望をもたらしています。

がん診断市場傾向/促進要因：

がん罹患率の上昇

ライフスタイルの変化、環境暴露、高齢化、遺伝的素因など、さまざまな要因によってがんの罹患率が上昇しています。遺伝子変異の蓄積や潜在的な発がん物質への曝露期間の長期化により、がんを患う人が増えています。加えて、食生活の乱れや運動不足といったライフスタイルの変化も、がんリスクを高める一因となっています。これとは別に、がんの効果的な治療のために早期発見を好む人が増えています。さらに、個人のさらなる合併症を避けるため、正確でタイムリーながん診断に対する需要の高まりが、市場の成長に寄与しています。このほか、医療サービスへのアクセスが向上していることも、市場の成長を後押ししています。

診断技術の進歩

各メーカーは、より高い感度、特異性、利用しやすさを提供するため、診断技術をますます進化させています。これに伴い、次世代シーケンシングやリキッドバイオプシーなどの分子・遺伝子検査技術は、さまざまな種類のがんに関連する特定のバイオマーカーの検出を可能にします。これらの技術は、腫瘍の特徴に関する洞察を提供し、カスタマイズされた治療アプローチを可能にします。これとは別に、陽電子放射断層撮影法（PET-CT）や磁気共鳴画像法（MRI）などの画像診断法の革新は、診断や病期分類に役立つ腫瘍のより詳細で正確な可視化を提供します。加えて、技術の継続的な進歩ががん診断の精度を高めており、市場の見通しは明るいです。

病気の早期発見に対する意識の高まり

がんの早期発見の重要性に対する消費者の意識の高まりが、市場の成長を後押ししています。個人は健康状態をモニターするために定期的な検診や診断検査を受けるようになっています。さらに、医療プロバイダーや組織は、早期介入の利点について一般大衆を教育するために数多くのキャンペーンを実施しており、それによって積極的な健康追求行動を促進しています。これとは別に、早期発見は治療成績を向上させるだけでなく、進行期がんに関連する全体的な医療負担を軽減します。各国の行政機関や医療機関は、利用しやすい検診プログラムを提供し、タイムリーながん診断の重要性を強調しています。このような取り組みにより、個人が定期的にがん検診を受けるようになり、市場にプラスの影響を与えています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のがん診断市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 消耗品
    • 主要セグメント
      • 抗体
      • キット・試薬
      • プローブ
      • その他
  • 機器
    • 主要セグメント
      • 病理ベース機器
      • イメージング機器
      • バイオプシー機器

第7章 市場内訳：技術別

  • IVD検査
    • 主要セグメント
      • ポリメラーゼ連鎖反応（PCR）
      • インサイチューハイブリダイゼーション（ISH）
      • 免疫組織化学（IHC）
      • 次世代シーケンシング（NGS）
      • マイクロアレイ
      • フローサイトメトリー
      • イムノアッセイ
      • その他
  • イメージング
    • 主要セグメント
      • 磁気共鳴画像法（MRI）
      • コンピュータ断層撮影（CT）
      • 陽電子放出断層撮影（PET）
      • マンモグラフィー
      • 超音波
  • バイオプシー技術

第8章 市場内訳：適応別

  • 乳がん
  • 肺がん
  • 大腸がん
  • 黒色腫
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院と診療所
  • 診断検査室
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • GE HealthCare（General Electric Company）
    • Hologic Inc.
    • Illumina Inc.
    • Koninklijke Philips N.V.
    • Pfizer Inc.
    • Qiagen N.V
    • Quest Diagnostics
    • Siemens Healthineers AG（Siemens AG）
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Cancer Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer Diagnostics Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Cancer Diagnostics Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Cancer Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Cancer Diagnostics Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Cancer Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Cancer Diagnostics (Consumables) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cancer Diagnostics (Consumables) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cancer Diagnostics (Instruments) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cancer Diagnostics (Instruments) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cancer Diagnostics (IVD Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cancer Diagnostics (IVD Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cancer Diagnostics (Imaging) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cancer Diagnostics (Imaging) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cancer Diagnostics (Biopsy Technique) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cancer Diagnostics (Biopsy Technique) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cancer Diagnostics (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cancer Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cancer Diagnostics (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cancer Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cancer Diagnostics (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cancer Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cancer Diagnostics (Melanoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cancer Diagnostics (Melanoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cancer Diagnostics (Other Cancers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cancer Diagnostics (Other Cancers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cancer Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cancer Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cancer Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cancer Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cancer Diagnostics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cancer Diagnostics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia-Pacific: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia-Pacific: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Cancer Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 83: Middle East and Africa: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Cancer Diagnostics Industry: SWOT Analysis
  • Figure 85: Global: Cancer Diagnostics Industry: Value Chain Analysis
  • Figure 86: Global: Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Cancer Diagnostics Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Cancer Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Cancer Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Cancer Diagnostics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Cancer Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cancer Diagnostics Market: Competitive Structure
  • Table 8: Global: Cancer Diagnostics Market: Key Players
目次
Product Code: SR112025A6322

The global cancer diagnostics market size reached USD 207.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 326.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.88% during 2025-2033. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

Cancer diagnostics identifies and determines the presence, type, and stage of cancer among individuals. It comprises a range of techniques and technologies, such as magnetic resonance imaging (MRI), X-rays, and laboratory tests, that analyze blood, tissue, and genetic samples. It allows healthcare professionals to accurately detect and assess cancerous growths within the body. It also enables healthcare providers to optimize patient outcomes by tailoring interventions to the specific characteristics of the disease. It assists in enhancing treatment decisions and developing personalized therapeutic strategies.

At present, the increasing preference for non-invasive diagnostic approaches that minimize discomfort and invasiveness among individuals is contributing to the growth of the market. Besides this, the rising demand for cost-effective and accurate diagnostics techniques is strengthening the market growth. In line with this, the increasing integration of artificial intelligence (AI), machine learning (ML), and data analytics in cancer diagnostics to enable quicker and more accurate results is propelling the growth of the market. Apart from this, governing agencies and healthcare authorities of several countries are organizing campaigns to spread awareness about cancer and its diagnostics among the masses worldwide. Furthermore, the growing demand for personalized medicines, along with the improving healthcare infrastructure around the world, is offering a positive market outlook.

Cancer Diagnostics Market Trends/Drivers:

Rising prevalence of cancer

There is a rise in the incidence of cancer due to various factors, such as lifestyle changes, environmental exposures, aging population, and genetic predisposition. People are increasingly suffering from cancer due to accumulated genetic mutations and longer exposure periods to potential carcinogens. In addition, lifestyle changes, such as poor diet and limited physical activity, is contributing to higher cancer risk. Apart from this, people are increasingly preferring early detection for effective treatment of cancer. Additionally, the rising demand for accurate and timely cancer diagnosis to avoid further complications among individuals is contributing to the growth of the market. Besides this, the increasing accessibility to healthcare services is bolstering the growth of the market.

Advancements in diagnostics techniques

Manufacturers are increasingly advancing their diagnostic technologies to offer greater sensitivity, specificity, and accessibility. In line with this, molecular and genetic testing techniques, such as next-generation sequencing and liquid biopsies, enable the detection of specific biomarkers associated with different types of cancer. These technologies provide insights into tumor characteristics and allow customized treatment approaches. Apart from this, innovations in imaging modalities, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors that aid in diagnosis and staging. In addition, the continuous advancement in technologies enhances the precision of cancer diagnostics, which is offering a positive market outlook.

Growing awareness about early detection of diseases

Increasing consumer awareness about the importance of early cancer detection is bolstering the growth of the market. Individuals are seeking regular screenings and diagnostic tests to monitor their health conditions. Moreover, healthcare providers and organizations are organizing numerous campaigns to educate the public about the benefits of early intervention, thereby promoting proactive health-seeking behavior. Apart from this, early detection not only improves treatment outcomes but reduces the overall healthcare burden associated with advanced-stage cancer. Governing agencies and healthcare institutions of various countries are providing accessible screening programs and emphasizing the importance of timely cancer diagnosis. These initiatives encourage individuals to go for regular screening for cancer, which is positively influencing the market.

Cancer Diagnostics Industry Segmentation:

Breakup by Product:

  • Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
  • Others
  • Instruments
  • Pathology-based Instruments
  • Imaging Instruments
  • Biopsy Instruments

Consumables comprise a wide range of products used in the process of cancer diagnostics. These include reagents, test kits, stains, and antibodies that are utilized in various diagnostic procedures, such as immunohistochemistry, molecular testing, and blood-based assays. In addition, consumables play a crucial role in facilitating accurate sample processing, analysis, and interpretation. The rising adoption of consumables due to the increasing demand for diagnostic testing in cancer care is bolstering the growth of the market.

Instruments refer to the equipment and devices employed to perform diagnostic tests and procedures. This category encompasses a diverse range of technologies, such as imaging equipment, laboratory equipment, and diagnostic platforms. Apart from this, there is a rise in the innovation of diagnostic instruments to improve the accuracy, speed, and efficiency of cancer diagnostics.

Breakup by Technology:

  • IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
  • Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound

Biopsy Technique

Imaging accounts for the majority of the market share

Imaging technologies involve the usage of advanced medical equipment to visualize internal structures and detect abnormalities within the body. Imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, and ultrasound, provide detailed images of tumors and their size, location, and potential metastases. These technologies aid in tumor detection, staging, and treatment monitoring. In line with this, they play a vital role in guiding medical decisions, enabling precise surgical interventions, and evaluating treatment responses.

Breakup by Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Breast cancer represents the largest market share

Breast cancer diagnostics comprise a wide range of methods for the early detection, diagnosis, and monitoring of breast tumors. Mammography is a widely used imaging technique that aids in detecting abnormalities, such as masses or microcalcifications. Besides this, biopsy procedures, such as core needle and fine-needle biopsies, provide tissue samples for pathological analysis that determine the nature and stage of the tumor. Molecular tests assess specific biomarkers like HER2/neu and estrogen receptor status. In addition, advanced imaging methods, such as breast MRI and molecular breast imaging, offer enhanced visualization and characterization of lesions.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others

Hospitals and clinics hold the biggest market share

Hospitals serve as comprehensive healthcare institutions that are equipped with advanced diagnostic equipment and expert medical personnel. They offer a wide range of cancer diagnostic services and provide comprehensive treatment planning based on diagnostic findings. On the other hand, clinics involve specialized cancer centers that cater to outpatient needs and often focus exclusively on cancer care. They offer diagnostics, such as mammograms and consultations, which makes it convenient for patients to receive timely evaluations. Both hospitals and clinics play pivotal roles in delivering accurate and efficient diagnostics for cancer patients.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest cancer diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the improved healthcare infrastructure. Apart from this, the rising focus on early detection of diseases among individuals is contributing to the growth of the market in the region. In line with this, the increasing awareness about cancer, along with favorable reimbursement policies, is propelling the growth of the market. Besides this, the presence of key diagnostic technology manufacturers, research institutions, and a strong network of healthcare facilities is bolstering the growth of the market in the North America region.

Competitive Landscape:

Major players are investing in research and development (R&D) activities to develop innovative diagnostic technologies. This involves exploring new biomarkers, improving imaging modalities, and enhancing the accuracy of molecular and genetic testing methods. In addition, diagnostic companies are continuously updating their existing technologies and platforms and incorporating artificial intelligence (AI) and machine learning (ML) algorithms for more accurate interpretation of diagnostic results. Apart from this, many companies are engaging in collaboration with research institutions, universities, and healthcare providers to gain expert knowledge and can access patient data for validation and improvement of diagnostic tools. Furthermore, key players are introducing new diagnostic products and services that focus on improved sensitivity, specificity, and ease of use.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • GE HealthCare (General Electric Company)
  • Hologic Inc.
  • Illumina Inc.
  • Koninklijke Philips N.V.
  • Pfizer Inc.
  • Qiagen N.V
  • Quest Diagnostics
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global cancer diagnostics market in 2024?
  • 2.What is the expected growth rate of the global cancer diagnostics market during 2025-2033?
  • 3.What are the key factors driving the global cancer diagnostics market?
  • 4.What has been the impact of COVID-19 on the global cancer diagnostics market?
  • 5.What is the breakup of the global cancer diagnostics market based on the technology?
  • 6.What is the breakup of the global cancer diagnostics market based on the application?
  • 7.What is the breakup of the global cancer diagnostics market based on the end user?
  • 8.What are the key regions in the global cancer diagnostics market?
  • 9.Who are the key players/companies in the global cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Kits and Reagents
      • 6.1.2.3 Probes
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Pathology-based Instruments
      • 6.2.2.2 Imaging Instruments
      • 6.2.2.3 Biopsy Instruments
    • 6.2.3 Market Forecast

7 Market Breakup by Technology

  • 7.1 IVD Testing
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction (PCR)
      • 7.1.2.2 In Situ Hybridization (ISH)
      • 7.1.2.3 Immunohistochemistry (IHC)
      • 7.1.2.4 Next-generation Sequencing (NGS)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Flow Cytometry
      • 7.1.2.7 Immunoassays
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Imaging
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Magnetic Resonance Imaging (MRI)
      • 7.2.2.2 Computed Tomography (CT)
      • 7.2.2.3 Positron Emission Tomography (PET)
      • 7.2.2.4 Mammography
      • 7.2.2.5 Ultrasound
    • 7.2.3 Market Forecast
  • 7.3 Biopsy Technique
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Melanoma
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GE HealthCare (General Electric Company)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Koninklijke Philips N.V.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen N.V
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quest Diagnostics
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Siemens Healthineers AG (Siemens AG)
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Thermo Fisher Scientific Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis